Albany Molecular Research Inc
AMRI
AMRI was delisted on the 31st of August, 2017.
136 hedge funds and large institutions have $677M invested in Albany Molecular Research Inc in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 48 increasing their positions, 34 reducing their positions, and 38 closing their positions.
266% more call options, than puts
Call options by funds: $7.94M | Put options by funds: $2.17M
53% more capital invested
Capital invested by funds: $443M → $677M (+$234M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
41% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 34
5% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 38
2% less funds holding
Funds holding: 139 → 136 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$41.5M |
| 2 |
Citigroup
New York
|
+$25.1M |
| 3 |
WIC
Water Island Capital
New York
|
+$19.7M |
| 4 |
CCM
Chicago Capital Management
Chicago,
Illinois
|
+$17.9M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIP
Permian Investment Partners
Dallas,
Texas
|
-$44.6M |
| 2 |
OWP
Obermeyer Wealth Partners
Aspen,
Colorado
|
-$24.8M |
| 3 |
RA
Royce & Associates
New York
|
-$20.4M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$17.3M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.72M |
AMRI Hedge Fund Activity: Q2 2017 in Review
136 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q2 2017, worth a combined $677M — up 53% from $443M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of AMRI and 36 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 48 added.
The largest buyer was Deutsche Bank, adding an estimated $41.5M. The largest seller was Permian Investment Partners, exiting entirely with an estimated $44.6M sold.
- 136 institutional investors held Albany Molecular Research Inc (AMRI) as of Q2 2017, down from 139 in Q1 2017.
- Funds reported $677M of Albany Molecular Research Inc stock for Q2 2017, up 53% quarter-over-quarter.
- 36 funds opened new Albany Molecular Research Inc positions in Q2 2017 and 38 closed out, a net change of -2 holders.
- The largest Albany Molecular Research Inc buyer in Q2 2017 was Deutsche Bank, an estimated $41.5M added.
- The largest Albany Molecular Research Inc seller in Q2 2017 was Permian Investment Partners, an estimated $44.6M sold.
Based on aggregated 13F filings for Q2 2017.